Emerging research suggests a compelling partnership between the GLP-1/GIP receptor agonist, another novel drug , and NAD+ . While this medication and retatrutide have demonstrated remarkable results in addressing metabolic dysfunction and promoting weight loss , evidence now hints at that supplementing metabolic performance with NAD+ could substant